Theranica, an Israel-based bio-medical technology company developing advanced electroceuticals for migraine and other pain conditions has partnered with Cove, a healthcare company that provides increased access to innovative migraine treatments. This partnership will enable customers to access Nerivio™, a novel FDA-authorized prescribed wearable for acute treatment of migraine, on Cove’s advanced telemedicine platform.
Read more Theranica Envisions a World of Non-Pharmacological Medical Therapy Wearables
Before becoming available on Cove, Nerivio could only be accessed in the nation’s leading headache clinics, located in limited geographic areas. Cove offers migraine sufferers immediate access to this potentially life-changing treatment, says a press release.
“Cove is dedicated to providing effective, specialized care to migraine sufferers via our telemedicine services and our ongoing care management,” said Caroline Hofmann, Cove’s General Manager. “We see Nerivio as an ideal addition to our platform, due to its intuitive and comfortable design, evidence-based efficacy and easy operation from a patient’s smartphone. We are excited to add this innovative acute migraine treatment option for migraine sufferers across the nation.”
As a non-invasive treatment option for acute migraine, Nerivio is being offered on Cove’s platform alongside a broad range of preventive and acute migraine treatments. The digital platform connects individuals with physicians to provide easy access to specialized migraine care. According to a recent article published in the Journal of Headache and Pain, Nerivio users reported comparable relief from migraines compared to acute pharmacological options.
The announcement follows a recent study published in Neurology that found telemedicine provides benefits of reduced costs, increased access and improved outcomes.
Read more HeadaTerm TENS Therapy Provides Fast Treatment for Acute Migraines, WAT Medical Study Reveals
“For those living with migraine, quick access to relief is a top priority and we are proud to partner with Cove to bring the benefits of Nerivio to more patients,” said Theranica co-founder and CEO Alon Ironi. “Cove’s service is designed to bring migraine relief to those in need simply and swiftly, and this partnership aligns with our mission of making digital health therapies both affordable and accessible.”
In addition to Nerivio, Cove now offers acute pain relief medications, preventative medications, anti-nausea medications, and clinically-proven supplements.
